Clinic Roundup

• ImmuneWorks Inc., of Indianapolis, said it completed a Phase I trial of Type V Collagen oral solution (IW001) in patients suffering from idiopathic pulmonary fibrosis. Thirty patients were enrolled in the 24-week study, which showed the drug to be well tolerated in preliminary results, with effects on lung function.